Immuron Ltd
ASX:IMC

Watchlist Manager
Immuron Ltd Logo
Immuron Ltd
ASX:IMC
Watchlist
Price: 0.038 AUD 2.7% Market Closed
Market Cap: AU$10.6m

Net Margin

-71.6%
Current
Improving
by 80.8%
vs 3-y average of -152.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-71.6%
=
Net Income
AU$-5.2m
/
Revenue
AU$7.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-71.6%
=
Net Income
AU$-5.2m
/
Revenue
AU$7.3m

Peer Comparison

Country Company Market Cap Net
Margin
AU
Immuron Ltd
ASX:IMC
10.6m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

In line with most companies in Australia
Percentile
45th
Based on 4 004 companies
45th percentile
-71.6%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Immuron Ltd
Glance View

Market Cap
10.6m AUD
Industry
Biotechnology

Immuron Ltd. engages in the research and development of oral immunotherapy, and product sales which focuses on bovine-colostrum with antibodies of choice for the treatment and prevention of a range of infectious and immune modulated diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in technology platform focused on the development and commercialization of a novel polyclonal antibodies to treat unmet medical needs. The firm operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. The firm's flagship products include Travelan & Protectyn. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn is an anti-LPS antibodies, which target and remove harmful bacteria and LPS toxins in the gut. The firm focused on clinical development of three drug candidates and several in early-stage preclinical development.

IMC Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-71.6%
=
Net Income
AU$-5.2m
/
Revenue
AU$7.3m
What is Immuron Ltd's current Net Margin?

The current Net Margin for Immuron Ltd is -71.6%, which is above its 3-year median of -152.3%.

How has Net Margin changed over time?

Over the last 3 years, Immuron Ltd’s Net Margin has increased from -373% to -71.6%. During this period, it reached a low of -373% on Jun 30, 2022 and a high of -71.6% on Jun 30, 2025.

Back to Top